[1]
G. De Danieli, F. Monari, R. Lazzarini, and F. Cipriani, “Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy”, FE, vol. 17, no. 3, Oct. 2016.